Posts

FDA Clears Lilly’s Weekly Insulin Onswik, Challenging Novo’s Awiqli

on
The FDA approved Eli Lilly’s Onswik (insulin efsitora alfa-gobe), a once-weekly basal insulin for adults with type 2 diabetes, on September 24, 2026. Onswik is intended to be used with diet and exercise to improve blood-sugar control and offers an alternative to daily long-acting insulin injections. Lilly plans to launch a prefilled Onswik KwikPen in the U.S. in the coming months, in 500 units/mL and 1,000 units/mL concentrations. The decision was supported by the Phase 3 QWINT program, which included more than 3,400 adults with type 2 diabetes. The trials found the drug non-inferior to daily basal-insulin comparators for glucose control. The approval intensifies competition with Novo Nordisk, whose once-weekly insulin Awiqli (insulin icodec) was cleared by the FDA in March 2026 and was the first weekly basal insulin available in the U.S. The products extend the Lilly–Novo rivalry beyond GLP-1 diabetes and obesity medicines into the basal-insulin market. Weekly dosing could r...

Travere CEO Eric Dube to Step Down

on

Novo Nordisk signs up to €1.165 billion Nanexa drug-delivery deal

on

Friday Five: AI agents show promise and risk

on

Roche signs backloaded deal with Atavistik for allosteric CVRM drugs

on

AstraZeneca’s Breztri wins EU asthma approval, marking third major asthma clearance

on

Basecamp Research raises $140 million to advance AI-designed medicines

on

Merck’s $3B Eye-Drug Prospect Clears Pivotal Trial, but Safety Questions Remain

on

Lilly and InnoCare announce potential $3.35 billion, five-target drug-discovery deal

on

FDA Clears Elevar’s Lyrfigtu for FGFR2-Altered Bile Duct Cancer

on

GRAIL’s Galleri cancer blood test advances after mixed but favorable FDA panel vote

on

Trump FDA Nominee Supports Vaccine Safety but Treads Carefully on Mifepristone

on

Acadia’s Remlifanserin Misses Phase 2 Primary Endpoint but Advances in Alzheimer’s Psychosis

on